1. Home
  2. INNV vs PCRX Comparison

INNV vs PCRX Comparison

Compare INNV & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InnovAge Holding Corp.

INNV

InnovAge Holding Corp.

HOLD

Current Price

$11.07

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$25.39

Market Cap

999.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INNV
PCRX
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
999.0M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
INNV
PCRX
Price
$11.07
$25.39
Analyst Decision
Sell
Strong Buy
Analyst Count
1
4
Target Price
$7.00
$30.25
AVG Volume (30 Days)
246.1K
628.4K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.19
Revenue
$853,699,000.00
$541,533,000.00
Revenue This Year
$12.85
$6.78
Revenue Next Year
$8.88
$8.54
P/E Ratio
N/A
$134.63
Revenue Growth
11.76
26.04
52 Week Low
$3.18
$18.80
52 Week High
$12.64
$27.66

Technical Indicators

Market Signals
Indicator
INNV
PCRX
Relative Strength Index (RSI) 48.74 49.26
Support Level $10.93 $22.03
Resistance Level $12.63 $26.94
Average True Range (ATR) 0.58 1.04
MACD -0.17 -0.13
Stochastic Oscillator 31.41 39.71

Price Performance

Historical Comparison
INNV
PCRX

About INNV InnovAge Holding Corp.

InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: